In a recent video interview, Kathy Schilling, M.D., discussed findings from a study of ProFound AI, an adjunctive artificial intelligence (AI) software for digital breast tomosynthesis (DBT), that demonstrated a 23 percent increase in breast cancer detection in comparison to DBT alone.
In a study involving over 100,000 digital breast tomosynthesis (DBT) screening exams, researchers found the use of ProFoundAI (iCAD), an adjunctive artificial intelligence (AI) software for digital breast tomosynthesis (DBT), increased sensitivity by 5 percent, increased the positive predictive value by 23 percent and increased the breast cancer detection rate by 23 percent for nine fellowship-trained breast radiologists with an average of 22 years of experience.
In a recent interview, Kathy Schilling, M.D., a co-author of the study, conceded a fair amount of surprise with the results.
“We have nine dedicated breast radiologists. That is all we do: mammography and breast imaging studies. We thought we were pretty good. It was really quite interesting and surprising that everyone improved their cancer detection by using the ProFound AI (software),” noted Dr. Schilling, the medical director of the Christine E. Lynn Women’s Health and Wellness Institute at the Boca Raton Regional Hospital in Florida.
Dr. Schilling pointed out these increases were achieved without an increase in recall rate.
“We’re not calling more patients back to find more cancers. We’re actually finding more cancers that we may have missed if we (did not) have the use of the ProFound AI,” added Dr. Schilling, who recently presented the study findings at the European Congress of Radiology.
(Editor’s note: For related content, see “Large Mammography Study Reaffirms Benefits of Digital Breast Tomosynthesis,” “Study: AI Improves Cancer Detection Rate for Digital Mammography and Digital Breast Tomosynthesis” and “FDA Issues Final Rule on National Breast Density Notification for Mammography Reports.”)
In a time of significantly increased imaging volume, Dr. Schilling said the ProFound AI software refocuses radiologists to detecting smaller cancers that may have otherwise gone undetected. In the study, she noted the researchers were diagnosing invasive lobular carcinoma, which commonly presents as architectural distortions, down to three to five millimeters in size.
For more insights from Dr. Schilling, watch the video below.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.